MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Third Quarter 2019 Financial Results Conference Call
October 30, 2019 16:05 ET | MacroGenics, Inc.
Rockville, MD, Oct. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MacroGenics, ViewRay, Cadence Bancorp, and ProPetro and Encourages Investors to Contact the Firm
October 30, 2019 16:00 ET | Bragar Eagel & Squire
NEW YORK, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
October 25, 2019 07:30 ET | MacroGenics, Inc.
Rockville, MD, Oct. 25, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Canada Goose, Meredith Corporation, MacroGenics, and ViewRay and Encourages Investors to Contact the Firm
October 23, 2019 19:09 ET | Bragar Eagel & Squire
NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
October 22, 2019 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Oct. 22, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Macrogenics, ViewRay, Cadence Bancorp, and ProPetro and Encourages Investors to Contact the Firm
October 15, 2019 20:54 ET | Bragar Eagel & Squire
NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Macrogenics, Inc. (NASDAQ:...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta Therapeutics, Canada Goose, Meredith Corporation, and MacroGenics and Encourages Investors to Contact the Firm
October 09, 2019 08:00 ET | Bragar Eagel & Squire
NEW YORK, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sarepta Therapeutics, Inc....
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta Therapeutics, Canada Goose, Meredith Corporation, and MacroGenics and Encourages Investors to Contact the Firm
October 02, 2019 21:07 ET | Bragar Eagel & Squire
NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sarepta Therapeutics, Inc....
MacroGenics-Logo-(transparent-background).png
MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress
September 30, 2019 03:20 ET | MacroGenics, Inc.
ROCKVILLE, MD, Sept. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Cantor Global Healthcare Conference
September 26, 2019 07:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Sept. 26, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...